fluorodeoxyglucose f18 has been researched along with verapamil in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balkay, L; Galuska, L; Goda, K; Juhász, I; Krasznai, Z; Márián, T; Mikecz, P; Nagy, H; Szabó, G; Szincsák, N; Trón, L | 1 |
| Boerman, O; Corstens, F; de Geus-Oei, LF; Molthoff, C; Oyen, W; van Eerd-Vismale, J | 1 |
| Balkay, L; Krasznai, Z; Krasznai, ZT; Márián, T; Szabó-Péli, J; Trón, L | 1 |
| Hatano, E; Higashi, T; Ikai, I; Iwaisako, K; Kitamura, K; Nakajima, A; Nakamoto, Y; Seo, S; Tada, M; Tamaki, N; Uemoto, S | 1 |
| Conrad, EU; Eary, JF; Krohn, KA; Link, JM; Mankoff, DA; Muzi, M; White, JK | 1 |
| Artigas, C; Carrió, I; Deportos, J; Fernández, Y; Flotats, A; Gaeta, C; Geraldo, L; Pavía, J | 1 |
| Deng, S; Wan, W; Wu, Y; Yen, TC; Yu, C; Zhang, B | 1 |
| Bol, A; Demeure, F; Gerber, B; Hanin, FX; Jamar, F; Pasquet, A; Pouleur, AC; Vancraeynest, D; Vanoverschelde, JL; Vincent, MF | 1 |
| Bacharach, S; Cussó, L; Desco, M; Vaquero, JJ | 1 |
| Masdeu, JC; Pascual, B; Rostomily, RC; Turkheimer, F; Veronese, M; Zanotti-Fregonara, P | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and verapamil
| Article | Year |
|---|---|
A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging.
Topics: Adult; Coronary Vessels; Diet; Fatty Acids, Nonesterified; Female; Fluorodeoxyglucose F18; Healthy Volunteers; Humans; Inflammation; Lipids; Male; Olive Oil; Plant Oils; Plaque, Atherosclerotic; Positron-Emission Tomography; Prospective Studies; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed; Verapamil | 2014 |
9 other study(ies) available for fluorodeoxyglucose f18 and verapamil
| Article | Year |
|---|---|
In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Humans; Metabolic Clearance Rate; Mice; Mice, SCID; Radioisotope Dilution Technique; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tissue Distribution; Tomography, Emission-Computed; Verapamil | 2003 |
Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals.
Topics: DNA; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Humans; Idoxuridine; Iodine Radioisotopes; Male; Methyltyrosines; Neoplasms; Organophosphorus Compounds; Organotechnetium Compounds; Radiopharmaceuticals; Verapamil | 2004 |
Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane Permeability; Daunorubicin; Drug Resistance, Multiple; Fluorodeoxyglucose F18; Humans; Membrane Fluidity; Mice; NIH 3T3 Cells; Phosphorylcholine; Rhodamine 123; Technetium Tc 99m Sestamibi; Verapamil | 2005 |
P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cell Differentiation; Disease Progression; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 2; Glucose-6-Phosphatase; Hexokinase; Humans; Liver Neoplasms; Models, Biological; Radionuclide Imaging; Tumor Cells, Cultured; Verapamil | 2009 |
Multiagent PET for risk characterization in sarcoma.
Topics: Carbon Dioxide; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Isotope Labeling; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Risk Assessment; Sarcoma; Thymidine; Verapamil | 2011 |
Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection.
Topics: Animals; Biological Transport; Calcium Channel Blockers; Fluorodeoxyglucose F18; Male; Mice; Mice, Inbred C57BL; Myocardium; Plaque, Atherosclerotic; Positron-Emission Tomography; Verapamil | 2011 |
Evaluation of the relationship between [18F]FDG and P-glycoprotein expression: an experimental study.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Positron-Emission Tomography; Prohibitins; Rhodamine 123; Technetium Tc 99m Sestamibi; Verapamil | 2012 |
Comparison of methods to reduce myocardial 18F-FDG uptake in mice: calcium channel blockers versus high-fat diets.
Topics: Animal Feed; Animals; Calcium Channel Blockers; Diet, Ketogenic; Female; Fluorodeoxyglucose F18; Heart; Mice; Mice, Inbred C57BL; Myocardium; Positron-Emission Tomography; Radiography; Verapamil | 2014 |
The validity of
Topics: Animals; Biomarkers; Biopsy; Blood-Brain Barrier; Brain; Brain Neoplasms; Carbazoles; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Genotype; Humans; Indoles; Inflammation; Ligands; Loperamide; Multiple Sclerosis; Positron-Emission Tomography; Protein Binding; Purines; Receptors, GABA; Reproducibility of Results; Verapamil | 2019 |